皓宸医疗(002622) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥142,937,780.75, a decrease of 12.58% compared to ¥163,503,563.10 in the same period last year[5] - The net loss attributable to shareholders was ¥12,214,580.55, representing a 167.13% increase in losses from ¥4,572,538.15 year-over-year[5] - Net profit for the period was a loss of ¥18,003,655.24, compared to a loss of ¥7,025,281.32 in the previous period, representing an increase in losses of approximately 156.5%[19] - Total operating revenue decreased to ¥142,937,780.75 from ¥163,503,563.10, a decline of approximately 12.5% year-over-year[17] - Total operating costs reduced to ¥167,162,234.16 from ¥179,781,974.53, a decrease of about 7.1% year-over-year[17] - Other comprehensive income after tax was a loss of ¥3,764,533.94, compared to a gain of ¥900,341.54 in the previous period[19] - Total comprehensive income for the period was a loss of ¥21,768,189.18, compared to a loss of ¥6,124,939.78 in the previous period[19] Cash Flow - The net cash flow from operating activities was negative at ¥17,184,700.35, a decline of 43.83% compared to the previous year's figure of ¥-11,948,253.48[5] - Cash flow from operating activities showed a net outflow of ¥17,184,700.35, worsening from a net outflow of ¥11,948,253.48 in the prior period[19] - Investment activities cash outflow totaled 278,026.75, resulting in a net cash flow from investment activities of -278,026.75[20] - Financing activities cash outflow amounted to 4,008,248.21, leading to a net cash flow from financing activities of -4,008,248.21[20] - The net increase in cash and cash equivalents was -21,470,870.05, with an ending balance of 125,099,938.62[20] - The beginning balance of cash and cash equivalents was 146,570,808.67[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,457,181,348.51, down 2.69% from ¥1,497,483,643.54 at the end of the previous year[5] - Current assets decreased from CNY 296,422,510.85 to CNY 271,723,944.04, a reduction of about 8.3%[13] - Non-current assets decreased from CNY 1,201,061,132.69 to CNY 1,185,457,404.47, indicating a decline of approximately 1.3%[14] - Total liabilities decreased from CNY 1,054,436,349.33 to CNY 1,035,902,243.48, a decrease of about 1.4%[14] - The company's cash and cash equivalents decreased from CNY 147,693,180.87 to CNY 126,548,983.48, a decline of approximately 14.3%[13] - Accounts receivable decreased from CNY 39,169,433.88 to CNY 32,094,965.57, reflecting a decrease of about 18.0%[13] - Inventory decreased slightly from CNY 50,753,348.55 to CNY 49,266,292.91, a reduction of approximately 2.9%[13] - The company's short-term borrowings remained relatively stable, decreasing slightly from CNY 191,588,304.03 to CNY 191,458,466.67[14] - The total equity attributable to shareholders of the parent company decreased to ¥382,056,059.67 from ¥398,035,174.16, a decline of approximately 4.0%[18] - The total liabilities and equity amounted to ¥1,457,181,348.51, down from ¥1,497,483,643.54, reflecting a decrease of about 2.7%[18] Research and Development - Research and development expenses increased by ¥2,600,000, marking a 163% rise compared to the same period last year[8] - Research and development expenses increased significantly to ¥4,192,860.44 from ¥1,594,263.46, marking a rise of about 162.5% year-over-year[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 54,029, with the largest shareholder holding 23.81% of the shares[10] Government Support - The company received government subsidies amounting to ¥328,966.43, which positively impacted other income[7] Other Information - The company has not audited its first-quarter report[21] - The financial report for the year 2025 will first apply new accounting standards[22]